+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 3
Age: 12Years - 80Years
All Genders
ID07249632

Phase III Trial of Telitacicept for Treating Ocular Myasthenia Gravis in Patients Aged 12 to 80

Led by RemeGen Co., Ltd. · Updated on 2026-04-09

120

Participants Needed

1

Research Sites

8 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are investigating the effectiveness and safety of Telitacicept for treating Ocular Myasthenia Gravis OMG, a condition classified as Type I by the Myasthenia Gravis Foundation of America. This Phase III, multicenter, randomized, double-blind, placebo-controlled study will enroll about 120 participants aged 12 to 80 years who have OMG and are on stable standard-of-care treatment. The study aims to compare Telitacicept with placebo in improving eye-related symptoms over 24 weeks. Participants will be randomly assigned to receive either Telitacicept or a matching placebo, with dosing based on age and body weight. The study groups are stratified by acetylcholine receptor antibody status and age groups under or over 18 years. The treatment period lasts 24 weeks, during which safety and side effects will be carefully monitored by an independent committee. During the study, participants will undergo evaluations including the Myasthenia Gravis Impairment Index focusing on eye symptoms, daily living activities, clinical scores, and quality of life assessments. Safety will be checked with physical exams, vital signs, lab tests, and adverse event monitoring from enrollment until four weeks after the last dose. The trial will measure changes in ocular symptoms from baseline to the end of treatment to assess treatment impact.

CONDITIONS

Brief Title

A Study of Telitacicept in Patients With Ocular Myasthenia Gravis (OMG)

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here